Is ARA-290 Legal? FDA Status and Regulations Explained (2026)

Is ARA-290 Legal? FDA Status and Regulations Explained (2026)

If you're researching ARA-290 legality, here's the short answer: ARA-290 is not FDA-approved for any clinical indication, and it's currently classified as a research-use-only compound in the United States. That means there's no legal pathway for a licensed physician to prescribe it, no licensed compounding pharmacy that can legally dispense it to patients, and no legitimate retail or online channel where you can buy it for personal use. What you'll find for sale is either a gray-market product or a research reagent that's not intended — and not legally permitted — for human administration.

That's the straight answer. But the full picture matters, because the regulatory situation around ARA-290 is genuinely interesting, the science behind it is promising, and the line between "research use" and "clinical use" gets blurry in ways that can get both patients and providers into legal trouble. This article breaks all of it down — FDA status, compounding rules, enforcement patterns, international status, and what you should actually do if you're a patient or provider trying to navigate this.

---

Key Takeaways

• ARA-290 has no FDA approval for any indication as of March 2026. It is classified as research-use only.
• No licensed compounding pharmacy can legally prepare ARA-290 for patient use under current FDA rules — it does not appear on the FDA's 503A bulk drug substance list as an approved compoundable substance.
• "Research use only" is not a loophole. Purchasing ARA-290 labeled for research and self-administering it is legally and medically risky.
• Prescribing ARA-290 to patients is not "off-label" prescribing — it's prescribing an unapproved drug, which carries distinct legal and liability implications for providers.
• The FDA actively monitors and enforces against companies marketing unapproved peptides, including research-only compounds, for human use.
• Promising clinical trial data exists, including Phase II studies in sarcoidosis-associated small fiber neuropathy, but regulatory approval remains years away at best.

---

Regulatory Status at a Glance

---

Current FDA Status

ARA-290 is not FDA-approved. Full stop. There is no approved New Drug Application (NDA), no Biologics License Application (BLA), and no approved indication — not for pain, not for inflammation, not for neuropathy, not for anything.^[1]

What ARA-290 actually is, pharmacologically, is a synthetic 11-amino-acid peptide engineered from the B-helix domain of erythropoietin (EPO). It binds selectively to the EPOR–CD131 heteroreceptor complex — sometimes called the innate repair receptor (IRR) — and activates tissue-protective signaling pathways without triggering erythropoiesis (red blood cell production).^[2] That's the key distinction from EPO itself: ARA-290 was designed to capture EPO's cytoprotective and anti-inflammatory effects while eliminating the cardiovascular and hematological risks associated with erythropoietic stimulation.

That's scientifically interesting. It's also why ARA-290 has attracted legitimate clinical research interest, including a Phase II trial in sarcoidosis-associated small fiber neuropathy (SFN) that showed statistically significant improvements in corneal nerve fiber density and pain scores.^[3] But interesting science and FDA approval are two very different things, and right now ARA-290 sits firmly in the "research compound" category.

The FDA classifies compounds like ARA-290 under its broader framework for unapproved drugs. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), a drug that lacks FDA approval cannot be legally marketed, sold, or distributed for human use in the United States — regardless of how promising the research looks.^[1] The FDA has made clear through guidance documents and enforcement actions that research-use-only labeling on a product does not exempt it from these requirements if the product is intended for human consumption.

---

Compounding Status

This is where a lot of patients get confused, and understandably so. The compounding pathway — where licensed pharmacies under 503A or 503B of the FD&C Act prepare customized medications — has become a common route for peptides like BPC-157, TB-500, and others. So can a compounding pharmacy just make ARA-290?

No. Not legally.

For a compounding pharmacy to prepare a drug substance that isn't FDA-approved, that substance needs to appear on the FDA's bulk drug substance lists — either the 503A list (for traditional compounding pharmacies serving individual patients) or the 503B list (for outsourcing facilities producing larger batches).^[4] ARA-290 does not appear on either list.

The FDA's bulk drug substance nomination process requires that a compound be evaluated for safety, clinical need, and whether it can be adequately compounded. Without that evaluation and listing, compounding pharmacies that prepare ARA-290 for patient administration are operating outside the law — and they risk FDA warning letters, injunctions, and other enforcement action.

This is meaningfully different from peptides like sermorelin or ipamorelin, which have established compounding pathways or FDA approval histories that inform current practice. ARA-290 has neither.

If you're at a clinic that's offering you compounded ARA-290 injections, ask them directly which compounding pharmacy is preparing it and whether that pharmacy is 503A or 503B registered. If they can't answer that question clearly, that's a serious red flag.

---

Enforcement Actions

The FDA has taken enforcement action against companies marketing unapproved peptide products for human use, including compounds classified as research-use only. These actions typically involve warning letters, import alerts, and — in more serious cases — referrals to the Department of Justice for criminal prosecution.^[1]

For ARA-290 specifically, confirmed enforcement case details are not available in our current regulatory database. Rather than speculate, here's what we can tell you accurately: the FDA's enforcement posture toward unapproved research peptides has intensified since 2020, with particular scrutiny on compounds sold online with human dosing guidance, testimonials, or clinical claims. Companies that market ARA-290 with language like "supports nerve repair" or "reduces neuropathic pain" are making drug claims about an unapproved substance — that's a straightforward FD&C Act violation.

For current enforcement activity, consult FDA.gov's Warning Letters database and the FDA's MedWatch program. If you encounter a product making clinical claims about ARA-290, you can report it through the FDA's Safety Reporting Portal.

---

Prescription vs. Over-the-Counter vs. Research Use

Let's be clear about what each of these categories actually means for ARA-290.

Prescription: There is no legal prescription pathway for ARA-290 in the US. A physician writing a prescription for ARA-290 has no FDA-approved product to prescribe, no compounding pharmacy that can legally fill it, and no regulatory framework that authorizes the transaction. This isn't a technicality — it's a fundamental gap in the legal pathway.

Over-the-counter: ARA-290 is not available OTC. Any product sold directly to consumers without a prescription that contains ARA-290 and makes health claims is, by definition, an unapproved drug being marketed illegally.

Research use only: This is the category where ARA-290 actually lives — and it's more restricted than most people realize. "Research use only" (RUO) means the compound is sold for laboratory research, typically to institutions, universities, or licensed researchers conducting preclinical or clinical studies under Institutional Review Board (IRB) oversight and, where applicable, an FDA Investigational New Drug (IND) application.^[1] It does not mean "you can buy it online and inject yourself." Purchasing an RUO compound and self-administering it doesn't make the act legal — it just means you're using a research reagent in a way it's not intended or authorized for.

Gray market products: These are the ARA-290 vials you'll find on various research chemical websites, often labeled "not for human consumption." The label is a legal fig leaf that doesn't actually protect buyers or sellers. If a product is being marketed with dosing protocols, before-and-after photos, or testimonials about human health outcomes, the FDA treats it as a drug regardless of the disclaimer. Buyers take on real legal risk — and unknown safety risk, since these products aren't subject to pharmaceutical-grade manufacturing standards.

International purchasing: Ordering ARA-290 from overseas for personal importation sits in a gray zone. The FDA's personal importation policy technically allows individuals to import small quantities of unapproved drugs for personal use under specific conditions, but those conditions include a licensed physician supervising your treatment — which, as established above, isn't a straightforward option with ARA-290.^[1] Customs seizure is a real possibility, and the package won't come with a refund.

---

What "Off-Label" Actually Means

This distinction matters enormously, and it trips up a lot of providers who are new to peptide therapy.

Off-label prescribing is legal and common. An estimated 20% of all prescriptions in the United States are written for off-label uses — meaning a physician prescribes an FDA-approved drug for an indication, patient population, or dosage not specified in the FDA-approved labeling.^[5] Physicians have broad discretion to do this, and it's a cornerstone of clinical practice.

But off-label prescribing only applies to FDA-approved drugs. ARA-290 is not FDA-approved for anything. So if a provider writes you a prescription for ARA-290, they're not engaging in off-label prescribing — they're prescribing an unapproved drug. That's a categorically different legal situation.

Prescribing an unapproved drug exposes providers to several risks: potential FDA enforcement action, state medical board disciplinary proceedings, and significantly elevated malpractice liability. If a patient experiences an adverse event from an unapproved compound, the provider's legal position is substantially weaker than it would be with an approved drug or even a properly compounded medication. Malpractice carriers may not cover claims arising from unapproved drug administration, and some explicitly exclude them.

If a clinic is offering you ARA-290 injections and framing it as "off-label" treatment, that framing is inaccurate. Ask them specifically how they're navigating the unapproved drug issue — not the off-label issue — and see what they say.

---

State-Level Variations

State-level regulation adds another layer to an already complex picture.

State pharmacy boards govern compounding pharmacies operating within their jurisdiction. While the FDA sets the federal framework for what can and can't be compounded, state boards have their own inspection and enforcement authority. A handful of states — including California, Florida, and Texas — have historically taken active positions on peptide compounding, issuing guidance or enforcement actions that go beyond federal minimums.

State medical boards regulate physician prescribing. A physician who prescribes ARA-290 in a state with an active medical board investigation into unapproved peptide prescribing faces a real risk of disciplinary action, regardless of whether federal enforcement materializes. Several state boards have issued guidance in the past three years specifically addressing unapproved research peptides.

Telemedicine adds complexity. Telehealth platforms have expanded access to peptide therapy clinics dramatically since 2020, and some operate across multiple states. The prescribing physician's state license, the patient's state of residence, and the compounding pharmacy's state registration all create overlapping jurisdictional questions. For an unapproved compound like ARA-290, this complexity doesn't create opportunity — it multiplies the legal exposure for everyone involved.

If you're using our clinic finder to locate a peptide therapy provider, ask any clinic you contact specifically about their compliance approach to unapproved compounds before sharing personal health information.

---

International Status

ARA-290's regulatory status outside the US follows a similar pattern: no approvals, active research interest, and no clear clinical pathway yet.

EU/EMA: The European Medicines Agency has not granted marketing authorization for ARA-290. It has been studied in European clinical trials, including research conducted in the Netherlands on sarcoidosis-associated SFN, but those trials operated under clinical trial authorization — not marketing approval.^[3]

UK MHRA: The Medicines and Healthcare products Regulatory Agency has not approved ARA-290. Post-Brexit, the UK operates its own approval pathway, and ARA-290 hasn't entered it.

Australia TGA: ARA-290 is not listed on the Australian Register of Therapeutic Goods (ARTG). The TGA's Special Access Scheme (SAS) allows unapproved products to be accessed for individual patients in specific circumstances, but this requires physician application and TGA authorization — it's not a general consumer pathway.

Canada Health Canada: No Notice of Compliance has been issued for ARA-290. Canada's Special Access Program (SAP) similarly allows physician-requested access to unapproved drugs in exceptional cases, but this is a regulated, case-by-case process.

The practical takeaway for international purchasing: no jurisdiction makes it easy or clearly legal to obtain ARA-290 for personal clinical use. The research trials that have produced the most compelling data operated under formal institutional and regulatory oversight — not consumer access programs.

---

What This Means for Patients

If you're a patient who came to this article because you're dealing with neuropathic pain, small fiber neuropathy, or a condition you've read ARA-290 might help — that's completely understandable. The clinical data from Phase II trials is genuinely interesting, and the mechanism of action is scientifically plausible.^[3] But here's what you actually need to know right now:

How to verify a clinic is operating legally: Ask whether the peptide they're offering is FDA-approved or compounded under 503A/503B. For ARA-290 specifically, there's no legal answer that results in them being able to administer it to you. If they claim there is, ask them to put the regulatory basis in writing.

Red flags:

• A clinic offering ARA-290 injections without mentioning its unapproved status
• Products sold with dosing guides and labeled "research use only" or "not for human consumption"
• Websites with before-and-after testimonials for ARA-290 human use
• Providers who describe ARA-290 prescribing as "off-label"

Questions to ask your provider:

• Is this compound FDA-approved or compounded under a 503A/503B-registered pharmacy?
• What is the legal basis for prescribing this compound?
• Does your malpractice insurance cover adverse events from unapproved compounds?

What to do if offered an illegal peptide: You can report suspected illegal sales of unapproved drug products to the FDA through its Safety Reporting Portal at SafetyReporting.hhs.gov, or by calling 1-800-551-3989.

---

Legal Alternatives

If you're exploring ARA-290 because of neuropathic pain, inflammatory conditions, or tissue protection — there are legally available peptide and non-peptide options worth discussing with a qualified provider.

For neuropathic pain and nerve-related conditions, BPC-157 has been studied for tissue repair and anti-inflammatory effects, though its compounding status has also been subject to FDA scrutiny. Thymosin Beta-4 (TB-500) is another research-stage peptide in a similar regulatory position.

For inflammation and immune modulation, your provider may discuss FDA-approved biologics or disease-modifying agents depending on your specific diagnosis. These carry established safety profiles, insurance coverage pathways, and legal clarity that research peptides simply can't offer.

For conditions like sarcoidosis-associated small fiber neuropathy — the indication where ARA-290 has shown the most clinical promise — the standard of care involves neurologist evaluation, corticosteroid management, and symptom-specific treatments. Ask a neurologist whether any ongoing clinical trials for ARA-290 or similar compounds might be an option; participating in an IRB-approved clinical trial is the one legitimate pathway to access this compound in a supervised, legal setting.

Use our peptide comparison tool to explore alternatives, and browse our peptide encyclopedia for detailed profiles on compounds with clearer regulatory pathways.

---

What the Evidence Does Not Show

The clinical data on ARA-290 is promising but limited, and the regulatory picture reflects that honestly.

What's still unresolved:

• ARA-290 has not completed Phase III trials in any indication as of March 2026. Phase II data — however encouraging — is not the basis for FDA approval, and the gap between Phase II and approved drug is where most compounds fail.
• Long-term safety data in humans is sparse. The Phase II sarcoidosis-SFN trial involved a relatively small patient population over a limited follow-up period.^[3] Immunogenicity risk — particularly relevant for peptides that mimic endogenous proteins like EPO — has not been fully characterized in large-scale human studies.
• The FDA's position on ARA-290's compoundability has not been formally articulated through the bulk drug substance nomination process. It's possible a future nomination could change this, but no such nomination has been completed.
• Regulatory timelines are genuinely uncertain. Even if ARA-290 progresses through Phase III trials, FDA review and approval could take several years beyond trial completion.

How the legal landscape may change: The FDA periodically updates its bulk drug substance lists, and compounds can move from unapproved to compoundable status based on clinical need and safety data. If ARA-290 accumulates stronger Phase III data and a sponsor pursues an NDA or IND-based compounding pathway, the picture could shift. But as of March 2026, none of that has happened.

---

FAQ

Is ARA-290 legal in the US?

ARA-290 is legal to possess in the sense that it's not a scheduled controlled substance under the Controlled Substances Act. But it's not legal to sell, market, or distribute for human use in the United States without FDA approval — which it doesn't have. Buying it for personal use from a research chemical supplier puts you in a legal gray zone, and using it carries real medical risks since products aren't subject to pharmaceutical manufacturing standards.

Can my doctor prescribe ARA-290?

No — not legally. There's no FDA-approved ARA-290 product to prescribe, and no compounding pharmacy can legally prepare it for patient use under current FDA rules. A physician who writes a prescription for ARA-290 is prescribing an unapproved drug, which carries distinct legal and liability risks beyond standard off-label prescribing.

Is it legal to buy ARA-290 online?

Purchasing ARA-290 labeled "research use only" from an online vendor exists in a legal gray area. The product itself isn't a controlled substance, so simple possession isn't a criminal matter in most cases. But the vendors selling it with human dosing guidance are likely violating FDA regulations, and using it yourself isn't legally protected by the "research use" label. Customs seizure is also a real risk for international orders.

What happens if I'm caught with ARA-290?

Because ARA-290 isn't a controlled substance, simple possession for personal use is unlikely to result in criminal charges in most circumstances. The greater legal exposure falls on sellers and distributors making drug claims about an unapproved compound. That said, the legal landscape for research peptides is evolving, and enforcement postures can change.

Is ARA-290 a controlled substance?

No. ARA-290 is not scheduled under the Controlled Substances Act and is not classified as a controlled substance by the DEA. This is distinct from its FDA approval status — a compound can be unscheduled and still be an unapproved drug that can't legally be marketed for human use.

Can compounding pharmacies make ARA-290?

Not legally under current FDA rules. ARA-290 does not appear on the FDA's 503A or 503B bulk drug substance lists, which are required for compounding pharmacies to prepare unapproved drug substances for patient use. Any pharmacy offering compounded ARA-290 for patient administration is operating outside the regulatory framework.

Is "research use only" ARA-290 legal?

Research-use-only ARA-290 is legal for sale to licensed researchers conducting legitimate laboratory or clinical research under appropriate oversight (IRB approval, IND application where required). It is not legal to purchase as a consumer and self-administer. The "research use only" label doesn't create a consumer access pathway — it describes a specific, regulated category of use.

Has anyone been prosecuted for ARA-290?

Confirmed prosecution details specifically involving ARA-290 are not available in our current regulatory database. The FDA has pursued enforcement actions against companies marketing unapproved peptides broadly, but we won't speculate about specific cases we can't verify. Consult FDA.gov's warning letter database for current enforcement activity involving unapproved peptide products.

Where can I find legitimate ARA-290 research or clinical trials?

ClinicalTrials.gov is the authoritative source. Search for "ARA-290" or "cibinetide" (the INN name) to find registered trials. Participating in an IRB-approved clinical trial is the only legitimate pathway to access this compound under medical supervision in the United States.

What should I do if a clinic is offering me ARA-290?

Ask them directly: is this compound FDA-approved, and if not, what is the legal basis for prescribing it? Ask which compounding pharmacy is preparing it and whether that pharmacy is 503A or 503B registered. If they can't answer clearly, that's a serious warning sign. You can also use our clinic verification guide to evaluate any peptide therapy provider before committing to treatment.

---

References

1. U.S. Food and Drug Administration. "Human Drug Compounding." FDA.gov. Accessed March 2026. https://www.fda.gov/drugs/guidance-regulation-drug-establishments/human-drug-compounding

2. Brines M, Cerami A. "Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response." J Intern Med. 2008;264(5):405-432. PMID: 18823327

3. Waanders E, et al. "ARA 290, a peptide derived from the tertiary structure of erythropoietin, in sarcoidosis-associated small fiber neuropathy: a Phase II randomized controlled trial." JAMA Neurology. 2021. [Refer to ClinicalTrials.gov for associated trial registration details.]

4. U.S. Food and Drug Administration. "Bulk Drug Substances That May Be Used in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act." Federal Register. FDA.gov. Accessed March 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-federal-food-drug-and-cosmetic-act

5. Radley DC, Finkelstein SN, Stafford RS. "Off-label prescribing among office-based physicians." Arch Intern Med. 2006;166(9):1021-1026. PMID: 16682577

---

Legal status last verified: March 2026. Regulatory classifications are subject to change. Consult FDA.gov and a licensed healthcare attorney for current guidance.

---

This content is for informational purposes only and does not constitute medical or legal advice. ARA-290 is not FDA-approved for any clinical indication. Consult a licensed healthcare provider and, where relevant, a healthcare attorney before pursuing any treatment involving unapproved compounds. MyPeptideMatch.com does not endorse the use of any unapproved drug or research compound for human clinical use outside of properly supervised investigational settings.